Chemistry:Duvortuxizumab
From HandWiki
Short description: Monoclonal antibody
Monoclonal antibody | |
---|---|
Type | Single-chain variable fragment |
Source | Chimeric/Humanized hybrid (mouse/human) |
Target | CD19 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG | |
Chemical and physical data | |
Formula | C4850H7485N1305O1487S35 |
Molar mass | 108989.98 g·mol−1 |
Duvortuxizumab (INN[1]) is a chimeric/humanized monoclonal antibody designed for the treatment of B-cell malignancies.[2]
This drug was developed by Janssen Global Services.[3]
References
- ↑ World Health Organization (2016). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 116". WHO Drug Information 30 (4). https://www.who.int/medicines/publications/druginformation/innlists/PL116.pdf.
- ↑ "Potent antitumor activity of duvortuxizumab, a CD19 x CD3 DART® molecule, in lymphoma models.". Cancer Research. July 2017. doi:10.1158/1538-7445.AM2017-3636.
- ↑ Statement On A Nonproprietary Name Adopted By The USAN Council - Duvortuxizumab, American Medical Association.
![]() | Original source: https://en.wikipedia.org/wiki/Duvortuxizumab.
Read more |